Table 1 Clinical impact summary
From: Clinical utility of custom-designed NGS panel testing in pediatric tumors
Tumor type | Number of patients | Any clinical Impact | Diagnostic impact | Prognostic impact | Potential change to therapy | Potential Germline alteration | ||
|---|---|---|---|---|---|---|---|---|
Tier 1 and 2 | Result changed diagnosis | Tier 1 and 2 | Change based on prognosis | Targeted therapy | ||||
CNS | 96 | 87 (90.6%) | 87 (90.6%) | 3 (3.1%) | 80 (83.3%) | 75 (78.1%) | 5 (5.2%) | 26 (27.1%) |
Leukemia/lymphoma | 124 | 110 (88.7%) | 104 (83.9%) | 4 (3.2%) | 65 (52.4%) | 22 (17.7%) | 7 (5.7%) | 8 (6.5%) |
Solid (non-CNS) | 147 | 92 (62.6%) | 73 (49.7%) | 5 (3.4%) | 36 (24.5%) | 34 (23.1%) | 32 (21.8%) | 37 (25.2%) |
Total | 367 | 289 (78.7%) | 264 (71.9%) | 12 (3.3%) | 181 (49.1%) | 131 (35.7%) | 44 (12.0%) | 71 19.3%) |